Back to Search Start Over

Barinthus lays off 25% of staff, sidelines prostate cancer program to stretch out cash.

Barinthus lays off 25% of staff, sidelines prostate cancer program to stretch out cash.

Authors :
Waldron, James
Source :
FierceBiotech; 6/13/2024, pN.PAG-N.PAG, 1p
Publication Year :
2024

Abstract

Barinthus used positive data from a pair of phase 2 trials for its hepatitis B therapy as justification for jettisoning a quarter of its workforce. [ABSTRACT FROM AUTHOR]

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
177909711